Skip to main content
. Author manuscript; available in PMC: 2013 Oct 24.
Published in final edited form as: Lab Invest. 2011 Feb 7;91(5):691–703. doi: 10.1038/labinvest.2011.5

Figure 5.

Figure 5

(a) Effects of mevalonate (200 μmol/l), LY294002 (10 μmol/l), Akt inhibitor SH-5 (10 μmol/l), γ-secretase inhibitor DAPT (20 μmol/l) and NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (1 mmol/l) on pitavastatin (100 nmol/l) 30 min-induced Akt activation (p-Akt), Notch1 cleavage (c-Notch1) and Hes-1 expression. Experiments were performed three times with similar results. (b) Representative immunoblots showing total and phosphorylated Akt (t- and p-Akt), C-terminal fragment of presenilin 1 (c-Presenilin 1), Jagged-1, total and cleaved Notch (t- and c-Notch1) and Hes-1 expression in human umbilical vein endothelial cells transfected with Akt small-interfering RNA (siRNA) in the absence or presence of pitavastatin (100 nmol/l, 30 min). Three independent experiments provided similar results.